Skip to Main Content

Paper Details

High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient.
Cancer Immunol Immunother
20
2021
CD163+, CD163+cells, CD3+, CD3+and CD8+T cells, CD4+, CD4+T cells, CD8, CD8+, CD8+T memory cells, GBM, GBMs, Glioblastomas, Lynch syndrome, MMR, MMR genes, MMR mutations, MSH2 (, MSH2 (R359S) gene, R359S, R359S) gene, T-cell, anti-PD1, blood, germline, glioblastoma, mismatch-repair, mismatch-repair (MMR) genes, nGBM, patient, patients, rGBM, recurrent, temozolomide, tumor, woman
Author NameAffiliation
Marica EoliFondazione IRCCS Istituto Neurologico Carlo Besta
Bianca PolloFondazione IRCCS Istituto Neurologico Carlo Besta
Antonio IavaroneInstitute for Cancer Genetics, Columbia University Medical Center
Antonio IavaroneInstitute for Cancer Genetics, Columbia University Medical Center
Raul RabadanInstitute for Cancer Genetics, University of Columbia
Gaetano FinocchiaroFondazione IRCCS Istituto Neurologico Carlo Besta
Gaetano FinocchiaroFondazione IRCCS Istituto Neurologico Carlo Besta
  • 1 - 7

Datasets

Release 1.2